Lifeward completes acquisition of Oratech Pharma, issues shares and convertible notes

Lifeward Ltd.

• Lifeward completed acquisition of Oratech Pharma on March 25, 2026, issuing 2,256,476 ordinary shares and pre-funded warrants to Oramed.
• Issued $10,000,000 aggregate principal amount of senior secured convertible notes and warrants in a private placement.
• Directors Dr. John William Poduska and Randel Richner resigned effective March 25, 2026.
• Appointed Nadav Kidron, Miriam Kidron, and Yehuda Reznick as new directors, expanding board from five to eight.
• Entered into a First Amendment and Assignment to assign Oratech Pharma rights to Oratech Ltd.